南财智讯1月23日电，华东医药在投资者关系活动中表示，2026年公司国内医美板块有望获批上市的产 品包括注射用重组A型肉毒毒素（YY001）、Ellansé®伊妍仕®M型（用于改善颞部凹陷）、V30射频 +强脉冲光+Nd:YAG激光多功能平台机，以及新型含利多卡因透明质酸钠填充剂MaiLi®Precise（眶下凹 陷适应症）。 ...

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

作为国内唯一同时持有合规"少女针"、"童颜针"两大再生填充产品，且同时还有肉毒毒素，水光针和黄金微针等重磅三类医疗器械医美品种的企业，四环医 药童颜针凭借左旋聚乳酸(PLLA)微球核心成分，实现"即时填充+长效再生"的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全性与临床疗 效均表现优异，多数患者注射後1年仍能维持有效效果。 中信证券研报称，四环医药肉毒毒素等医美产品快速增长，再生类新品童颜针与少女针上市后机构拿货积极、销售超预期；中长期受益于多产品协同及面向 医美机构的一体化解决方案，医美业务有望持续高速增长。维持四环医药"买入"评级，目标价1.6港元。(格隆汇) 四环医药(0460.HK)今日高开高走，盘中涨5.51%至1.34港元。消息面上，四环医药近日公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸 面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准。这是继该产品首次获批后的又一重要进展，进一步完善了公司在再生医 美产品领域的市场布局。此次新增规格包括60mg/瓶、80mg/瓶、100mg/瓶、110mg/瓶、120mg/瓶、130mg/瓶，将进一步 ...

1月23日，四环医药(0460.HK)今日高开高走，盘中涨5.51%至1.34港元。消息面上，四环医药近日公告，集团旗下渼颜空间 生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批 准。这是继该产品首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。此次新增规格包括 60mg/瓶、80mg/瓶、100mg/瓶、110mg/瓶、120mg/瓶、130mg/瓶，将进一步丰富产品选择谱系。 责任编辑：栎树 股票频道更多独家策划、专家专栏，免费查阅>> 作为国内唯一同时持有合规"少女针"、"童颜针"两大再生填充产品，且同时还有肉毒毒素，水光针和黄金微针等重磅三类医 疗器械医美品种的企业，四环医药童颜针凭借左旋聚乳酸(PLLA)微球核心成分，实现"即时填充+长效再生"的双重功效，其 独特专利技术保障了微球形态规则、粒径均一，安全性与临床疗效均表现优异，多数患者注射後1年仍能维持有效效果。中 信证券研报称，四环医药肉毒毒素等医美产品快速增长，再生类新品童颜针与少女针上市后机构拿货积极、销售超预期； 中长期受益于多产品协同及面向医美机构的一 ...

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

消息面上，近日，四环医药发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面 部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品首次获 批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 智通财经APP获悉，四环医药(00460)涨近4%，截至发稿，涨3.94%，报1.32港元，成交1282.5万港元。 此次规格拓展前，产品已获批45mg╱瓶、75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联 合治疗及综合年轻化等不同需求；新增获批的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、 120mg╱瓶、130mg╱瓶六类规格，将进一步丰富产品选择谱系。 ...

晨会纪要 核心结论 分析师 【策略】资产的信号（20260121）：中国经济 2026 会更好吗? 大类资产继续坚定看好 AH 股/国债等人民币资产，其中 A 股在"春季躁动" 之后仍会"有新高"，行业配置建议继续【有/新/高】组合（【有】色金属/【新】 消费/【高】端制造）。港股可趁低位布局，由于化债势在必行，国债存在修 复空间。贵金属和工业金属仍受益于大宗商品超级周期，美股&美债或维持 震荡。 【非银金融】瑞达期货（002961.SZ）更新点评：拟收购申港证券 11.94% 股权，强化证券期货协同 补足券商牌照，强化财富管理协同。公司已于 26 年 1 月完成转债转股，资 本实力进一步夯实。我们看好在期货行业稳中向好的态势下，公司依托自身 较强创新能力带来的业绩与份额的提升。预计 2025 年归母净利润同比 +30.1%至 4.98 亿元，维持"买入"评级。 | 周颖 S0800520080003 | | --- | zhouying@research.xbmail.com.cn 国内市场主要指数 | 指数名称 | 收盘 | 涨跌(%) | | --- | --- | --- | | 上证指数 | 4,1 ...

Group 1 - Meituan's medical beauty sector is facing aggressive price competition from Alibaba's e-commerce platform, Tmall, which has introduced significant discounts [1][2] - Tmall's "百亿补贴" (100 billion subsidy) strategy has led to the price of the "童颜针" (Aivilan, 84mg) dropping to 1399 yuan per unit, with potential discounts bringing it down to as low as 999 yuan [1][2] - In contrast, Meituan's pricing for the same product remains around 4000 yuan in the Beijing area, indicating a direct challenge to Meituan's market position [2] Group 2 - Meituan has established a strong market presence with nearly 9,500 new medical beauty institutions opened by August 2025, and over 200 upstream brands have joined its platform [3] - Tmall's strategy to attract users through subsidies is a response to the significant barriers Meituan has built with its extensive offline supply network [4] - The medical beauty market has already seen a price war initiated by competitors, such as New Oxygen, which introduced a product priced at 2999 yuan, significantly lower than the market average of 13,000 to 24,000 yuan [5]

证券日报网讯 1月21日，爱美客在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东人 数为61728户。 （文章来源：证券日报） ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has received approval from the National Medical Products Administration of China for its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution," marking a significant milestone in its product development [1][2]. - The company has successfully launched two key Class III medical devices, enhancing its competitive edge in the recombinant collagen sector [3]. - The dual product strategy addresses both wrinkle reduction and skin quality improvement, catering to diverse consumer needs in the aesthetic medicine market [2][3]. Financial Projections - Revenue is projected to grow from 3,524 million in 2023 to 7,204 million in 2027, with a peak growth rate of 57.2% in 2024 [4]. - Net profit is expected to increase from 1,452 million in 2023 to 2,630 million in 2027, with a notable growth rate of 44.9% in 2023 [4]. - Earnings per share (EPS) are forecasted to rise from 1.49 in 2023 to 2.46 in 2027, reflecting a strong upward trend in profitability [4]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 21.1 in 2023 to 12.8 in 2027, indicating an improving valuation as earnings grow [4]. - The price-to-book (P/B) ratio is expected to decline from 7.2 in 2023 to 2.7 in 2027, suggesting a more favorable valuation relative to book value over time [4].